FADS2 and obesity disorder: Particularly, lowering the AA content of phospholipids through regulation of FADS2 by dietary adjuncts, such as icosapent ethyl, could be a novel strategy to regulate moderately elevated corticoid production in obesity, a concept which merits clinical investigation (59).